Latest stories on EIKN
Eikon Therapeutics Highlights Promising Lung Cancer Trial Data
TipRanks64 · neutralproduct/pr
Eikon Therapeutics, Inc. (EIKN) files 8-K
SEC 8-K50 · neutralgeneral
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
Business Insider63 · neutralproduct/pr
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
GlobeNewswire63 · neutralproduct/pr
Eikon Therapeutics Highlights Promising PARP1 and WRN Data
TipRanks63 · neutralproduct/pr
Eikon Therapeutics, Inc. (EIKN) files 8-K
SEC 8-K50 · neutralgeneral
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Business Insider58 · neutralproduct/pr
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
GlobeNewswire58 · neutralproduct/pr
Eikon Therapeutics to present abstracts on clinical candidates at ESMO 2026
The Fly56 · neutralproduct/pr
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Business Insider56 · neutralproduct/pr
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
GlobeNewswire56 · neutralproduct/pr
Eikon Therapeutics submits EIK1006 IND application to FDA
The Fly58 · neutralproduct/pr
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Business Insider61 · neutralproduct/pr
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
GlobeNewswire63 · neutralproduct/pr
Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Inhibrx, Eikon rise after insider buying
Seeking Alpha63 · neutralgeneral
Eikon Therapeutics appoints Ching-Pin Chang as chief scientific officer
The Fly59 · neutralgeneral
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Business Insider55 · neutralgeneral
Eikon Therapeutics to Participate in Investor Conferences in September 2026
Business Insider56 · neutralgeneral
Eikon Therapeutics to Participate in Investor Conferences in September 2026
GlobeNewswire55 · neutralgeneral
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
Seeking Alpha63 · neutralproduct/pr
Eikon Therapeutics to Spotlight PARP Inhibitor Advances at Cantor Fitzgerald KOL Event
August 19, 2026
MarketChameleon56 · neutralproduct/pr
Eikon Therapeutics to Share Insights on PARP Inhibitors in Oncology at Cantor Fitzgerald KOL Event
August 19, 2026
MarketChameleon56 · neutralproduct/pr
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Business Insider56 · neutralproduct/pr
Eikon Therapeutics reports Q2 EPS ($1.63), consensus ($1.46)
The Fly34 · bearishearnings